Boehringer Ingelheim

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Boehringer Ingelheim
Feb 7, 2025, 18:49 | Blog
The launch of the final recommendations of SISAQOL-IMI - EORTC
EORTC (European Organisation for Research and Treatment of Cancer) shared a post on LinkedIn by…
Dec 25, 2024, 15:54 | Science
Daniel Gerlach: Pan-KRAS inhibitors displaying potent anti-tumor activity in tumors with KRAS allele amplification
Daniel Gerlach, Associate Scientific Director, Computational Biology Oncology at Boehringer Ingelheim, posted on X about…
Dec 9, 2024, 13:26 | Insight
First-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C
Daniel Gerlach, Associate Scientific Director, Computational Biology Oncology at Boehringer Ingelheim, shared a recent article…
Nov 19, 2024, 09:33 | Blog
Abstract Submission for the 2025 edition of Drugging and Regulating the MAP Kinase Pathway - EACR
European Association for Cancer Research - EACR shared on LinkedIn: "Submit your abstract by 16…
Nov 5, 2024, 17:45 | Blog
Herbert Loong: Another successful YATO24 supported by Boehringer Ingelheim
Herbert Loong, Chair-Elect of the International Affairs Committee at the American Society of Clinical Oncology,…
Oct 2, 2024, 10:30 | Insight
Richi Patient Empowerment Program: A New Initiative for Global Patient Associations
Richi Patient Empowerment shared on LinkedIn: “As we approach the end of Childhood Cancer Awareness…
Sep 30, 2024, 17:15 | Blog
Providing value beyond our mission while creating awareness and raising funds for the Richi House - Richi Patient Empowerment
Richi Patient Empowerment shared a post on LinkedIn: "As we approach the end of Childhood…
Sep 24, 2024, 09:00 | Blog
Lykke Hinsch Gylvin: What makes a Medical / Science Congress visit truly energizing
Lykke Hinsch Gylvin posted on LinkedIn: "This is what makes a Medical / Science Congress…
Sep 14, 2024, 13:46 | Blog
Hung Trinh: Top 10 CDMO ranking based on sales revenue and operation
Hung Trinh shared a post on LinkedIn: ''Who are in the top 10 CDMO ranking…
Aug 6, 2024, 11:41 | Insight
Norbert Kraut: Co-targeting of KRASG12C plus SOS1 for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors
Norbert Kraut,Global Head of Cancer Research at Boehringer Ingelheim, shared on X: "Out now in…
Jul 29, 2024, 23:26 | Blog
Lykke Hinsch Gylvin: Why we need to stop treating cancer – and start treating people
Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, posted…
Jun 29, 2024, 14:26 | Blog
QUANTRO Therapeutics Achieves Milestone with Boehringer Ingelheim in Developing First-in-Class Cancer Treatments
QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments,…
Jun 16, 2024, 02:46 | Blog
Herbert Loong: Welcoming Boehringer Ingelheim’s Clinical Operations Managment Team for a brief visit at our CUHK Medicine Department of Clinical Oncology
Herbert Loong shared a post on LinkedIn: “Had the pleasure of welcoming Boehringer Ingelheim’s Clinical…
Jun 11, 2024, 13:03 | Insight
Hanneke Pouw: Tomorrow I'll present our work in an oral presentation at the SNMMI24 in Toronto!
Hanneke Pouw, PhD candidate ImmunoPET at Amsterdam UMC, shared on LinkedIn: “Tomorrow I'll present our…
Apr 6, 2024, 08:28 | Blog
Dr. Mahmoud Ould-Kaci speaking about oncology drug portfolio at Boehringer Ingelheim at AACR24
Wafik S. El-Deiry, Director at the Legorreta Cancer Center at Brown University, shared on X/Twitter: "Listening…
Jan 12, 2024, 17:07 | Blog
Latest pharma industry updates by Nicolas Schmitz
Nicolas Schmitz, Senior Manager, Strategic Market Analyst at KBI Biopharma, shared a post on LinkedIn:…
Dec 24, 2023, 18:34 | Insight
Norbert Kraut: A must-read Precision Oncology: 2023 in Review
Norbert Kraut, Global Head of Cancer Research, Boehringer Ingelheim, shared on X/Twitter: "2023 has been…
All: 17 Posts: 1 - 100
Special Coverage